Levemir FlexPen (Insulin Detemir 100 U/mL) by Novo Nordisk is a pharmaceutical-grade long-acting insulin analogue delivered via a prefilled FlexPen injectable pen. Insulin detemir is a recombinant human insulin analogue with structural modifications that confer a prolonged and predictable pharmacokinetic profile, making it a well-documented subject of clinical research in basal glucose management for both Type 1 and Type 2 diabetes.
 
✔ Key Research Insights
Studied for its extended basal insulin coverage of up to 24 hours, with documented stable absorption profiles in research subjects receiving once or twice daily subcutaneous administration
Investigated for its low pharmacodynamic variability relative to intermediate-acting insulin preparations, associated with more predictable glucose-lowering activity in clinical observations
Researched for its reduced risk of nocturnal hypoglycaemia compared to NPH and other intermediate-acting insulin formulations in documented clinical trial populations
Examined for its flexible once or twice daily dosing options, supporting individualized basal insulin titration protocols across diverse diabetic subject populations
Documented for its capacity to mimic endogenous basal pancreatic insulin secretion, maintaining stable interstitial and serum glucose parameters between meals and during overnight fasting periods in clinical literature
Manufactured by Novo Nordisk to pharmaceutical-grade insulin innovation and quality standards
 
📦 Product Specifications
Manufacturer: Novo Nordisk
Product: Levemir FlexPen
Molecule: Insulin Detemir
Concentration: 100 U/mL
Appearance: Clear, colorless injectable solution
Form: Prefilled FlexPen (subcutaneous injection)
Volume: Box of 5 prefilled pens
Clinical reference: dosage should be determined by a qualified healthcare professional. Once or twice daily subcutaneous administration is indicated per individualized clinical protocols.
 
⚙ How It Works
Insulin detemir is a long-acting recombinant human insulin analogue in which threonine at position B30 is omitted and a C14 fatty acid chain is attached to lysine at position B29. This structural modification enables reversible binding to albumin in subcutaneous tissue and systemic circulation in research subjects, creating a depot effect that delays absorption and prolongs the duration of insulin activity relative to regular human insulin. Following subcutaneous administration, the gradual dissociation of insulin detemir from albumin binding sites results in a slow, consistent release of active insulin into systemic circulation, with clinical documentation of stable glucose-lowering activity extending up to 24 hours. The resulting pharmacokinetic profile closely approximates endogenous basal pancreatic insulin secretion patterns, maintaining hepatic and peripheral glucose homeostasis during fasting and inter-meal periods. In basal-bolus therapy protocols, insulin detemir is referenced as the basal component, administered independently of meal timing to address fasting glycaemic parameters across documented clinical populations.
 
⭐ Product Overview
Manufactured by Novo Nordisk, a globally recognized leader in insulin research, development, and pharmaceutical-grade production
Prefilled FlexPen delivery system supporting precise, consistent, and hygienic subcutaneous dosing per administration
Long-acting insulin analogue with a well-documented low-variability pharmacokinetic profile and established clinical efficacy in basal glucose management
Indicated for basal insulin support in both Type 1 and Type 2 diabetes management, as referenced across international endocrinological and diabetes care guidelines
Widely recognized in clinical and regulatory literature under the insulin detemir and Levemir designations worldwide